Botulinum toxin A for neuropathic pain after neck dissection: a dose-finding study

Area of Science:

• Neurology
• Pain Management
• Oncology

Background:

• Chronic neuropathic pain is a common complication following neck dissection.
• Botulinum toxin type A (BtxA) has shown potential for treating such pain.
• The optimal dosage of BtxA for this indication remains unestablished.

Purpose of the Study:

• To investigate the impact of different Botulinum toxin type A (BtxA) doses on chronic neuropathic pain after neck dissection.
• To assess the effect of BtxA on patients' quality of life.

Main Methods:

• A prospective, open-label phase II trial involving 23 patients with post-neck dissection neuropathic pain.
• Patients received either a low dose (10 MU/0.1 mL) or a high dose (20 MU/0.1 mL) of BtxA via subcutaneous injection.
• Pain severity (Visual Analog Scale) and quality of life (EORTC questionnaires) were evaluated at baseline and 28 days post-treatment.

Main Results:

• The low-dose BtxA group demonstrated a statistically significant reduction in pain (VAS score from 4.3 to 3.0, P<.05).
• The high-dose BtxA group did not show significant pain improvement.
• Trends toward improved quality of life were observed in the low-dose group, with no serious adverse events reported.

Conclusions:

• Low-concentration Botulinum toxin type A (BtxA) appears to be a viable therapeutic option for managing chronic neuropathic pain in the neck and shoulder region post-neck dissection.
• Further research may be warranted to confirm optimal dosing and long-term efficacy.